The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.
 
Manish R. Patel
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Bayer; Exelixis; Incyte
Research Funding - Abbvie (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); G1 Therapeutics (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Takeda (Inst); Tesaro (Inst)
 
Scott James Weir
Research Funding - CicloMed (Inst)
Patents, Royalties, Other Intellectual Property - Co-Inventor on issued Ciclopirox Prodrug composition-of-matter and methods-of-use patents
 
Robyn Wood
No Relationships to Disclose
 
Tammy Ham
Employment - CicloMed
Leadership - CicloMed
Stock and Other Ownership Interests - CicloMed
 
Crista Casey
No Relationships to Disclose
 
Greg Reed
No Relationships to Disclose
 
Prasad Dandawate
No Relationships to Disclose
 
Prabhu Ramamoorthy
No Relationships to Disclose
 
Michael Jay Baltezor
Employment - CritiTech
Patents, Royalties, Other Intellectual Property - Inventor on multiple patents that are pending and granted for CritiTech, Inc.
Travel, Accommodations, Expenses - CritiTech
 
Roy A. Jensen
No Relationships to Disclose
 
Benjamin L. Woolbright
No Relationships to Disclose
 
John Arthur Taylor
Honoraria - ASCO; Bristol-Myers Squibb; Photocure
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Ferring
Patents, Royalties, Other Intellectual Property - PCT/US11/21721. Use of Isoxazoline compounds and compositions in bladder cancer. Inventors: Taylor JA and Sielecki TM
Other Relationship - Photocure
 
Shrikant Anant
No Relationships to Disclose
 
Michael Dalton
No Relationships to Disclose
 
Valentina Zhukova-Harrill
No Relationships to Disclose
 
William McCulloch
Employment - 3-V Biosciences; CicloMed; Ribon Therapeutics
Leadership - 3-V Biosciences
Stock and Other Ownership Interests - 3-V Biosciences
Consulting or Advisory Role - CicloMed; Ribon Therapeutics
Patents, Royalties, Other Intellectual Property - Issued patents relating to romidepsin (Istodax(R)) assigned to Celgene, Inc. No financial interest.
Travel, Accommodations, Expenses - CicloMed; Ribon Therapeutics
 
Suzanne Fields Jones
Consulting or Advisory Role - Clovis Oncology (Inst); Janssen (Inst); Novartis (Inst); Onyx (Inst); Teva (Inst); Vertex (Inst)
 
Howard A. Burris
No Relationships to Disclose
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bioatla (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Precision Oncology (Inst); Regeneron (Inst); Rgenix (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Vegenics (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute